GLP-1 ProgrammeVial

Retatrutide 10mg

Triple agonist. The frontier of metabolic research.

$180USD
Order via Telegram →

Reply within 24 hours.

9AGLP-1

Important — Research framing

For research purposes only. Not approved for human use. Conservative titration and physician oversight strongly recommended. Consult a qualified physician before initiating any injectable peptide protocol.

Mechanism

How it works.

Simultaneously activates GLP-1, GIP, and glucagon receptors — the only triple-agonist peptide in current research protocols. Glucagon receptor activation adds a third metabolic axis unavailable in dual-agonist compounds.

Retatrutide represents the current frontier of metabolic peptide research. Early data shows superior body composition outcomes versus dual-agonists. Conservative titration is essential — this compound is significantly more potent per mg than Tirzepatide. 10mg lyophilised vial.

Research protocol

Titration schedule.

Reference titration based on published research protocols. We confirm your specific protocol fit in chat before fulfilment.

  1. Week 1–20.5mg

    Critical starting dose — do not skip. More potent per mg than Tirzepatide.

  2. Week 3–41.0mg

    Increase only if well-tolerated.

  3. Week 5–61.5mg
  4. Week 7+2.0mg

    Typical maintenance range for research protocols.

Order

Start Retatrutide 10mg.

Message us on Telegram. We'll confirm fit, walk through the titration, and ship within 24 hours.